Loading patent…
AssigneeAventis Pharma Deutschland GmbH
InventorKenneth J. CLEMESTON
Estimating the term…
The invention relates to Glycoprotein VI (GPVI), its isolation, purification, and methods for recombinant production. Especially, the invention relates to the use of GPVI, preferably recombinant GPVI, in the treatment of disorders and pathological events correlated directly or indirectly to blood coagulation disorders such as thrombotic and cardiovascular diseases. The extracellular recombinant protein can also be used for establishing screening assays to find potential inhibitors of the membrane bound GPVI in order to inhibit binding of thrombocytes and platelets, respectively, to collagen. Changes in GPVI can be used to monitor platelet age and exposure to thrombotic and cardiovascular diseases.
A DNA coding for Glycoprotein VI or a biologically active fragment thereof.
A DNA having the sequence of FIG. 2 (SEQ ID NO:
5-10. (canceled)
An isolated polynucleotide which is
An isolated polynucleotide which encodes a polypeptide comprising the amino acid sequence of FIG. 1B (SEQ ID NO:
A polynucleotide which encodes a polypeptide consisting essentially of the amino acid sequence set forth in SEQ ID NO:
A polynucleotide which encodes a polypeptide consisting essentially of the amino acid sequence of positions 1-249 of SEQ ID NO:
Dependencies are inferred from the claim text.